The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis

BMC Pulmonary Medicine

Table 3 Association of ACE gene D/I polymorphism with onset of clinical symptoms of patients in months considering the cohorts to CFTR mutation

Groups	*ACE*genotype	≤ 3 months	> 3 months	Total	X²	p	X²	p	OR (CI 5-95%)
Without taking CFTR mutation into account	I/I	38	28	66	0,880	0,644	0.012	0.9136	1.035 (0.555 - 1.931)
	I/D	44	37	81			0.473	0.492	0.808 (0.4396 -1.484)
	D/D	15	8	23			0.723	0.395	1.486 (0.5937, 3.721)
No identified CFTR mutation	I/I	13	6	19	1,685	0,431	0.825	0.364	1.806 (0.5017 -6.498)
	I/D	9	9	18			1.624	0.203	0.438 (0.122 - 1.576)
	D/D	3	1	4			0.357	0.977	2.045 (0.194 - 21.58)
One CFTR mutation identified class I, II or III	I/I	10	11	21	5,564	0,062	4.217	0.049	0.297 (0.084 – 0.995)
	I/D	14	6	20			0.521	0.471	1.167 (0.775 – 1.757)
	D/D	8	1	9			2.951	0.097	5,667 (0,647 – 49,61)
Two CFTR mutation identified class I, II and/or III	I/I	15	11	26	0,599	1,026	0.773	0.379	1.527 (0.593 - 3.936)
	I/D	21	22	43			0.122	0.727	0.854 (0.352 - 2.072)
	D/D	4	6	10			0.511	0.704	0.611 (0.158 - 2.358)

Values below 0.05 for p denote clinical correlation between variables. OR - odds ratio, CI- confidence interval, ≤ − less than or equal to, > − greater, D - deleted allele, I - insertion allele. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II or III.

ISSN: 1471-2466